There are about 21062 clinical studies being (or have been) conducted in Italy. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
Reminiscence group therapy is a brief and structured intervention that has been shown to be effective for improving well-being among older adults. Reminiscence helps accepting the ageing process by solving unresolved issues and past losses; the group setting empowers the efficacy of the process by giving back to elderly a way to manage their skills in a wider setting and interact with other people. The sharing of memories reinforces the identity through active tasks, preparing individuals to cope with the final part of the life. However, considering reminiscence interventions for older populations, controlled trials adopting better inclusion/exclusion criteria, standardized measures, and different conditions for comparing the effect are needed. According to this premise, the trial presents the design of a randomized controlled aimed at comparing group reminiscence therapy with a group recreational activity in a older population. It includes two groups of approximately 20 hospitalized elderly: (1) the Experimental Group, (2) the Control Group. Participants included in the Experimental Group will receive a group reminiscence therapy of six sessions, while the Control Group will participate in a recreational group discussion. Between design with repeated measures will be used to evaluate changes in self-reported outcome measures of depressive symptoms, self-esteem, life satisfaction, quality of life across baseline, post-intervention and three months post-intervention. What the investigators would like to show with the present trial is the efficacy of a group reminiscence intervention in a hospitalized population of older adults: focusing on specific past events and re-living them in a group environment may enhance the self-esteem and quality of life better than a simple group discussion.
Phase I, multicenter, open-label, dose escalation study to test the efficacy and safety of F8IL10 and methotrexate when given as a combination in rheumatoid arthritis patients.
This Phase II study is an uncontrolled, multicenter, prospective study for patients with malignant melanoma of the skin in clinical stage III or stage IV M1a. Twenty Patients will be treated with a mixture of L19IL2 and L19TNF once weekly for up to 4 weeks. The dose will be distributed among the lesions via multiple intralesional injections. The proportion of patients with complete response at week 12 will be calculated.
Prospective, open-label, non randomized, dose escalation study that will be conducted in sequential cohorts of patients.
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
Our hypothesis is that totally Implantable Venous Access Devices in neoplastic patients modify body image and self-representation. Therefore, the purpose of this study is to evaluate the efficacy of psychological intervention on patients undergone this surgical practice.
This study will assess efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
The primary objective is to demonstrate the non-inferiority of edoxaban (preceded by a short course of LMWH) compared with dalteparin for the prevention of the combined outcome of recurrent venous thromboembolism (VTE) or major bleeding in subjects with VTE associated with cancer during a 12-month study period. If non-inferiority is established, LMWH/edoxaban will be compared with dalteparin for superiority.
The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.
The purpose of this study is to demonstrate the superiority of iBGstar as a component of the diabetes treatment vs. traditional blood glucose self-monitoring system for improving glycemic control after 6 months in young patients with type 1 diabetes. The study is intended also to demonstrate the superiority of iBGStar as a component of the diabetes treatment vs. usual blood glucose self-monitoring system for improving the compliance to self monitoring of blood glucose after 6 months.